Timeliness and actionable intelligence over I-Banks research which remains only geared to institutional investors and legacy processes. News carries with it a promise of transparency, a light that can be shined into previously dark corners.
But they don’t define any relevance to the actual value of a release - mostly due to SEC forward looking parameters. However, this news portal has been expanded to … supplement, measure and price the event and relevance to a company’s ... valuation.
April 27, 2016
Cytori (CYTX) P3 Scleroderma trial update
April 1, 2016
RegMed Investors (RMi) it’s time to act on subscription!
March 31, 2016
Biostage ™ hits the limelight with a quantified focus - BUY
March 7, 2016
Spark Therapeutics (ONCE) acquires Genable Technologies
March 2, 2016
TiGenix NV (Euronext Brussels: TIG) submits MAA to EMA
February 22, 2016
Bellicum’s (BLCM) BPX-501 granted Orphan Drug Designation
February 17, 2016
RegMed Investors’ (RMi) motto is: Never leave an investor uninformed
January 22, 2016
Ocata Therapeutics (OCAT) another deadline looms for buyout
3 hours 26 min ago
RegMed Investors’ (RMi) closing bell; just another melt down
13 hours 20 min ago
RegMed Investors’ (RMi) pre-open indications; the current sector resistance
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at email@example.com.
Editor and Publisher ... Henry McCusker enters his thirteenth (13th) year at RegMed Investors